Detalhe da pesquisa
1.
A Novel Targeted RIG-I Receptor 5'Triphosphate Double Strain RNA-Based Adjuvant Significantly Improves the Immunogenicity of the SARS-CoV-2 Delta-Omicron Chimeric RBD-Dimer Recombinant Protein Vaccine.
Viruses
; 15(5)2023 04 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-37243185
2.
Establishment of national standard for anti-SARS-Cov-2 neutralizing antibody in China: The first National Standard calibration traceability to the WHO International Standard.
Front Immunol
; 14: 1107639, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-36865542
3.
Non-small cell lung cancers (NSCLCs) oncolysis using coxsackievirus B5 and synergistic DNA-damage response inhibitors.
Signal Transduct Target Ther
; 8(1): 366, 2023 09 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-37743418
4.
Establishment of the first Chinese national standard for protein subunit SARS-CoV-2 vaccine.
Vaccine
; 40(14): 2233-2239, 2022 03 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-35227521
5.
Transcriptomic analysis of the innate immune signatures of a SARS-CoV-2 protein subunit vaccine ZF2001 and an mRNA vaccine RRV.
Emerg Microbes Infect
; 11(1): 1145-1153, 2022 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-35343384
6.
Mixed formulation of mRNA and protein-based COVID-19 vaccines triggered superior neutralizing antibody responses.
MedComm (2020)
; 3(4): e188, 2022 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-36474858
7.
A Short 5'triphosphate RNA nCoV-L Induces a Broad-Spectrum Antiviral Response by Activating RIG-I.
Viruses
; 14(11)2022 11 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36366549
8.
A Novel Single-Stranded RNA-Based Adjuvant Improves the Immunogenicity of the SARS-CoV-2 Recombinant Protein Vaccine.
Viruses
; 14(9)2022 08 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-36146661
9.
Heterologous immunization with adenovirus vectored and inactivated vaccines effectively protects against SARS-CoV-2 variants in mice and macaques.
Front Immunol
; 13: 949248, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-36059554
10.
COVID-19 vaccines: progress and understanding on quality control and evaluation.
Signal Transduct Target Ther
; 6(1): 199, 2021 05 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-34006829
11.
Evaluation of the cross-neutralization activities elicited by Coxsackievirus A10 vaccine strains.
Hum Vaccin Immunother
; 17(12): 5334-5347, 2021 12 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34756160
12.
Cross-Antigenicity between EV71 Sub-Genotypes: Implications for Vaccine Efficacy.
Viruses
; 13(5)2021 04 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-33919184
13.
A uniform quantitative enzyme-linked immunosorbent assay for Coxsackievirus A16 antigen in vaccine.
Hum Vaccin Immunother
; 17(2): 381-388, 2021 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32750255
14.
Boosting with heterologous vaccines effectively improves protective immune responses of the inactivated SARS-CoV-2 vaccine.
Emerg Microbes Infect
; 10(1): 1598-1608, 2021 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-34278956
15.
Safety and immunogenicity of a recombinant COVID-19 vaccine (Sf9 cells) in healthy population aged 18 years or older: two single-center, randomised, double-blind, placebo-controlled, phase 1 and phase 2 trials.
Signal Transduct Target Ther
; 6(1): 271, 2021 07 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-34267185
16.
Development of a pseudovirus-based assay for measuring neutralizing antibodies against Coxsackievirus A10.
Hum Vaccin Immunother
; 16(6): 1434-1440, 2020 06 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-31851566
17.
A potential therapeutic neutralization monoclonal antibody specifically against multi-coxsackievirus A16 strains challenge.
Hum Vaccin Immunother
; 15(10): 2343-2350, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-30735461
18.
A neonatal mouse model of central nervous system infections caused by Coxsackievirus B5.
Emerg Microbes Infect
; 7(1): 185, 2018 Nov 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-30459302
19.
Construction and verification of an infectious cDNA clone of coxsackievirus B5.
Virol Sin
; 37(3): 469-471, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35288348